Stemline Therapeutics' lead pipeline candidate Elzonris was approved today for the treatment of blastic plasmacytoid dendritic cell neoplasmwell ahead of its February 21 FDA action date, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Elzonris is now the only approved drug for this orphan oncology indication, adds the analyst. His assessment of physician sentiment around the drug's clinical data package indicates that providers "are eager" to prescribe this targeted therapy. As such, Catanzaro thinks Elzonris should see rapid adoption in this setting. The analyst keeps an Overweight rating on Stemline Therapeutics with a $20 price target.